{"id":"https://openalex.org/W2144708402","doi":"https://doi.org/10.1200/jco.2005.05.004","title":"Rituximab Plus Short-Duration Chemotherapy As First-Line Treatment for Follicular Non-Hodgkin\u2019s Lymphoma: A Phase II Trial of the Minnie Pearl Cancer Research Network","display_name":"Rituximab Plus Short-Duration Chemotherapy As First-Line Treatment for Follicular Non-Hodgkin\u2019s Lymphoma: A Phase II Trial of the Minnie Pearl Cancer Research Network","publication_year":2005,"publication_date":"2005-01-05","ids":{"openalex":"https://openalex.org/W2144708402","doi":"https://doi.org/10.1200/jco.2005.05.004","mag":"2144708402","pmid":"https://pubmed.ncbi.nlm.nih.gov/15632411"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2005.05.004","doi":"https://doi.org/10.1200/jco.2005.05.004","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2005.05.004","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5065917441","display_name":"John Daniel Hainsworth","orcid":"https://orcid.org/0000-0002-2848-6546","observed_orcids":["https://orcid.org/0000-0002-2848-6546"]},"institutions":[{"id":"https://openalex.org/I4210100810","display_name":"Sarah Cannon","ror":"https://ror.org/014t21j89","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210100810"]},{"id":"https://openalex.org/I4210119499","display_name":"Thompson Cancer Survival Center","ror":"https://ror.org/02zhjb475","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210119499"]},{"id":"https://openalex.org/I4210135086","display_name":"Tennessee Oncology","ror":"https://ror.org/03754ky26","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210135086"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"John D. Hainsworth","raw_affiliation_strings":["From the Sarah Cannon Cancer Center and Tennessee Oncology, PLLC, Nashville; Thompson Cancer Survivor Center, Knoxville, TN; Northwest Georgia Oncology Centers, Marietta, GA; Consultants in Blood Disorders and Cancer, Louisville, KY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the Sarah Cannon Cancer Center and Tennessee Oncology, PLLC, Nashville; Thompson Cancer Survivor Center, Knoxville, TN; Northwest Georgia Oncology Centers, Marietta, GA; Consultants in Blood Disorders and Cancer, Louisville, KY","institution_ids":["https://openalex.org/I4210100810","https://openalex.org/I4210119499","https://openalex.org/I4210135086"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5089449243","display_name":"Sharlene Litchy","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210100810","display_name":"Sarah Cannon","ror":"https://ror.org/014t21j89","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210100810"]},{"id":"https://openalex.org/I4210119499","display_name":"Thompson Cancer Survival Center","ror":"https://ror.org/02zhjb475","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210119499"]},{"id":"https://openalex.org/I4210135086","display_name":"Tennessee Oncology","ror":"https://ror.org/03754ky26","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210135086"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sharlene Litchy","raw_affiliation_strings":["From the Sarah Cannon Cancer Center and Tennessee Oncology, PLLC, Nashville; Thompson Cancer Survivor Center, Knoxville, TN; Northwest Georgia Oncology Centers, Marietta, GA; Consultants in Blood Disorders and Cancer, Louisville, KY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the Sarah Cannon Cancer Center and Tennessee Oncology, PLLC, Nashville; Thompson Cancer Survivor Center, Knoxville, TN; Northwest Georgia Oncology Centers, Marietta, GA; Consultants in Blood Disorders and Cancer, Louisville, KY","institution_ids":["https://openalex.org/I4210100810","https://openalex.org/I4210119499","https://openalex.org/I4210135086"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5031741135","display_name":"Lisa H. Morrissey","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210100810","display_name":"Sarah Cannon","ror":"https://ror.org/014t21j89","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210100810"]},{"id":"https://openalex.org/I4210119499","display_name":"Thompson Cancer Survival Center","ror":"https://ror.org/02zhjb475","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210119499"]},{"id":"https://openalex.org/I4210135086","display_name":"Tennessee Oncology","ror":"https://ror.org/03754ky26","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210135086"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Lisa H. Morrissey","raw_affiliation_strings":["From the Sarah Cannon Cancer Center and Tennessee Oncology, PLLC, Nashville; Thompson Cancer Survivor Center, Knoxville, TN; Northwest Georgia Oncology Centers, Marietta, GA; Consultants in Blood Disorders and Cancer, Louisville, KY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the Sarah Cannon Cancer Center and Tennessee Oncology, PLLC, Nashville; Thompson Cancer Survivor Center, Knoxville, TN; Northwest Georgia Oncology Centers, Marietta, GA; Consultants in Blood Disorders and Cancer, Louisville, KY","institution_ids":["https://openalex.org/I4210100810","https://openalex.org/I4210119499","https://openalex.org/I4210135086"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5088164827","display_name":"Michael B. Andrews","orcid":"https://orcid.org/0000-0002-2969-4769","observed_orcids":["https://orcid.org/0000-0002-2969-4769"]},"institutions":[{"id":"https://openalex.org/I4210100810","display_name":"Sarah Cannon","ror":"https://ror.org/014t21j89","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210100810"]},{"id":"https://openalex.org/I4210119499","display_name":"Thompson Cancer Survival Center","ror":"https://ror.org/02zhjb475","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210119499"]},{"id":"https://openalex.org/I4210135086","display_name":"Tennessee Oncology","ror":"https://ror.org/03754ky26","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210135086"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Michael B. Andrews","raw_affiliation_strings":["From the Sarah Cannon Cancer Center and Tennessee Oncology, PLLC, Nashville; Thompson Cancer Survivor Center, Knoxville, TN; Northwest Georgia Oncology Centers, Marietta, GA; Consultants in Blood Disorders and Cancer, Louisville, KY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the Sarah Cannon Cancer Center and Tennessee Oncology, PLLC, Nashville; Thompson Cancer Survivor Center, Knoxville, TN; Northwest Georgia Oncology Centers, Marietta, GA; Consultants in Blood Disorders and Cancer, Louisville, KY","institution_ids":["https://openalex.org/I4210100810","https://openalex.org/I4210119499","https://openalex.org/I4210135086"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5089426504","display_name":"Manuel Grimaldi","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210100810","display_name":"Sarah Cannon","ror":"https://ror.org/014t21j89","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210100810"]},{"id":"https://openalex.org/I4210119499","display_name":"Thompson Cancer Survival Center","ror":"https://ror.org/02zhjb475","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210119499"]},{"id":"https://openalex.org/I4210135086","display_name":"Tennessee Oncology","ror":"https://ror.org/03754ky26","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210135086"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Manuel Grimaldi","raw_affiliation_strings":["From the Sarah Cannon Cancer Center and Tennessee Oncology, PLLC, Nashville; Thompson Cancer Survivor Center, Knoxville, TN; Northwest Georgia Oncology Centers, Marietta, GA; Consultants in Blood Disorders and Cancer, Louisville, KY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the Sarah Cannon Cancer Center and Tennessee Oncology, PLLC, Nashville; Thompson Cancer Survivor Center, Knoxville, TN; Northwest Georgia Oncology Centers, Marietta, GA; Consultants in Blood Disorders and Cancer, Louisville, KY","institution_ids":["https://openalex.org/I4210100810","https://openalex.org/I4210119499","https://openalex.org/I4210135086"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5069040094","display_name":"Matthew J. McCarty","orcid":"https://orcid.org/0000-0001-6515-9387","observed_orcids":["https://orcid.org/0000-0001-6515-9387"]},"institutions":[{"id":"https://openalex.org/I4210100810","display_name":"Sarah Cannon","ror":"https://ror.org/014t21j89","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210100810"]},{"id":"https://openalex.org/I4210119499","display_name":"Thompson Cancer Survival Center","ror":"https://ror.org/02zhjb475","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210119499"]},{"id":"https://openalex.org/I4210135086","display_name":"Tennessee Oncology","ror":"https://ror.org/03754ky26","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210135086"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Matthew McCarty","raw_affiliation_strings":["From the Sarah Cannon Cancer Center and Tennessee Oncology, PLLC, Nashville; Thompson Cancer Survivor Center, Knoxville, TN; Northwest Georgia Oncology Centers, Marietta, GA; Consultants in Blood Disorders and Cancer, Louisville, KY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the Sarah Cannon Cancer Center and Tennessee Oncology, PLLC, Nashville; Thompson Cancer Survivor Center, Knoxville, TN; Northwest Georgia Oncology Centers, Marietta, GA; Consultants in Blood Disorders and Cancer, Louisville, KY","institution_ids":["https://openalex.org/I4210100810","https://openalex.org/I4210119499","https://openalex.org/I4210135086"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5073724595","display_name":"F. Anthony Greco","orcid":"https://orcid.org/0009-0009-4578-0630","observed_orcids":["https://orcid.org/0009-0009-4578-0630"]},"institutions":[{"id":"https://openalex.org/I4210100810","display_name":"Sarah Cannon","ror":"https://ror.org/014t21j89","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210100810"]},{"id":"https://openalex.org/I4210119499","display_name":"Thompson Cancer Survival Center","ror":"https://ror.org/02zhjb475","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210119499"]},{"id":"https://openalex.org/I4210135086","display_name":"Tennessee Oncology","ror":"https://ror.org/03754ky26","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210135086"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"F. Anthony Greco","raw_affiliation_strings":["From the Sarah Cannon Cancer Center and Tennessee Oncology, PLLC, Nashville; Thompson Cancer Survivor Center, Knoxville, TN; Northwest Georgia Oncology Centers, Marietta, GA; Consultants in Blood Disorders and Cancer, Louisville, KY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the Sarah Cannon Cancer Center and Tennessee Oncology, PLLC, Nashville; Thompson Cancer Survivor Center, Knoxville, TN; Northwest Georgia Oncology Centers, Marietta, GA; Consultants in Blood Disorders and Cancer, Louisville, KY","institution_ids":["https://openalex.org/I4210100810","https://openalex.org/I4210119499","https://openalex.org/I4210135086"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":3,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":5.9149,"has_fulltext":false,"cited_by_count":45,"citation_normalized_percentile":{"value":0.96529851,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":89,"max":97},"biblio":{"volume":"23","issue":"7","first_page":"1500","last_page":"1506"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10685","display_name":"Viral-associated cancers and disorders","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/rituximab","display_name":"rituximab","score":0.9919999837875366},{"id":"https://openalex.org/keywords/follicular-non-hodgkin-s-lymphoma","display_name":"follicular non-Hodgkin's lymphoma","score":0.9679999947547913},{"id":"https://openalex.org/keywords/first-line-treatment","display_name":"first-line therapy","score":0.7670000195503235},{"id":"https://openalex.org/keywords/chop","display_name":"CHOP","score":0.7400000095367432},{"id":"https://openalex.org/keywords/central-venous-pressure","display_name":"central venous pressure","score":0.9869999885559082},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.8920000195503235},{"id":"https://openalex.org/keywords/complete-response","display_name":"complete response","score":0.6349999904632568},{"id":"https://openalex.org/keywords/treatment-related-toxicity","display_name":"treatment toxicity","score":0.597000002861023},{"id":"https://openalex.org/keywords/elderly-patients","display_name":"elderly patients","score":0.8410000205039978}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8787417411804199},{"id":"https://openalex.org/C2777058707","wikidata":"https://www.wikidata.org/wiki/Q123251","display_name":"Follicular lymphoma","level":3,"score":0.8226644992828369},{"id":"https://openalex.org/C2780653079","wikidata":"https://www.wikidata.org/wiki/Q412323","display_name":"Rituximab","level":3,"score":0.6508288383483887},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.6245925426483154},{"id":"https://openalex.org/C2779338263","wikidata":"https://www.wikidata.org/wiki/Q208414","display_name":"Lymphoma","level":2,"score":0.5654793977737427},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5588076114654541},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4545449912548065},{"id":"https://openalex.org/C187785154","wikidata":"https://www.wikidata.org/wiki/Q5464664","display_name":"Follicular phase","level":2,"score":0.43505001068115234},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.4272027909755707},{"id":"https://openalex.org/C2779251273","wikidata":"https://www.wikidata.org/wiki/Q43436","display_name":"Pearl","level":2,"score":0.42562854290008545},{"id":"https://openalex.org/C2992779791","wikidata":"https://www.wikidata.org/wiki/Q209369","display_name":"Hodgkin lymphoma","level":3,"score":0.418855220079422},{"id":"https://openalex.org/C27206212","wikidata":"https://www.wikidata.org/wiki/Q34178","display_name":"Theology","level":1,"score":0.0},{"id":"https://openalex.org/C138885662","wikidata":"https://www.wikidata.org/wiki/Q5891","display_name":"Philosophy","level":0,"score":0.0}],"mesh":[{"descriptor_ui":"D000069283","descriptor_name":"Rituximab","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000369","descriptor_name":"Aged, 80 and over","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000633","qualifier_name":"toxicity","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000633","qualifier_name":"toxicity","is_major_topic":false},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000633","qualifier_name":"toxicity","is_major_topic":false},{"descriptor_ui":"D003520","descriptor_name":"Cyclophosphamide","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D003520","descriptor_name":"Cyclophosphamide","qualifier_ui":"Q000633","qualifier_name":"toxicity","is_major_topic":false},{"descriptor_ui":"D004317","descriptor_name":"Doxorubicin","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D004317","descriptor_name":"Doxorubicin","qualifier_ui":"Q000633","qualifier_name":"toxicity","is_major_topic":false},{"descriptor_ui":"D005500","descriptor_name":"Follow-Up Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007275","descriptor_name":"Injections, Intravenous","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008224","descriptor_name":"Lymphoma, Follicular","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D008224","descriptor_name":"Lymphoma, Follicular","qualifier_ui":"Q000401","qualifier_name":"mortality","is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011241","descriptor_name":"Prednisone","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D011241","descriptor_name":"Prednisone","qualifier_ui":"Q000633","qualifier_name":"toxicity","is_major_topic":false},{"descriptor_ui":"D014750","descriptor_name":"Vincristine","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D014750","descriptor_name":"Vincristine","qualifier_ui":"Q000633","qualifier_name":"toxicity","is_major_topic":false},{"descriptor_ui":"D015996","descriptor_name":"Survival Rate","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D058846","descriptor_name":"Antibodies, Monoclonal, Murine-Derived","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1200/jco.2005.05.004","doi":"https://doi.org/10.1200/jco.2005.05.004","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2005.05.004","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},{"id":"pmid:15632411","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/15632411","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","raw_type":"Clinical Trial"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9940000176429749,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":19,"referenced_works":["https://openalex.org/W1662187404","https://openalex.org/W1874821077","https://openalex.org/W1912693401","https://openalex.org/W1915689252","https://openalex.org/W1979300931","https://openalex.org/W2032423298","https://openalex.org/W2058015212","https://openalex.org/W2104334201","https://openalex.org/W2106072062","https://openalex.org/W2122284431","https://openalex.org/W2150000105","https://openalex.org/W2161958805","https://openalex.org/W2166337528","https://openalex.org/W2167635913","https://openalex.org/W2168926834","https://openalex.org/W2200845149","https://openalex.org/W2241830411","https://openalex.org/W2511528602","https://openalex.org/W3041047318"],"related_works":["https://openalex.org/W2245586354","https://openalex.org/W2241830411","https://openalex.org/W2013002753","https://openalex.org/W2039021803","https://openalex.org/W1945026987","https://openalex.org/W2403988497","https://openalex.org/W2168759512","https://openalex.org/W2101939391","https://openalex.org/W2560147005","https://openalex.org/W2544322912"],"abstract_inverted_index":{"PURPOSE:":[0],"To":[1],"evaluate":[2],"the":[3,13,135,153],"feasibility":[4],"and":[5,68,74,87,99,137,144,203,247,259],"efficacy":[6],"of":[7,16,52,61,132,168,215,222,256],"rituximab":[8,53],"with":[9,18,27,124,198,212],"short-duration":[10],"chemotherapy":[11,63,189,237,246,263],"in":[12,166],"first-line":[14,194,254],"treatment":[15,195,255],"patients":[17,47,103,107,148,173,197,258],"follicular":[19,32,199],"non-Hodgkin's":[20],"lymphoma":[21],"(NHL).":[22],"PATIENTS":[23],"AND":[24],"METHODS:":[25],"Patients":[26,79],"previously":[28],"untreated":[29],"stage":[30],"II-IV":[31],"NHL,":[33],"grade":[34],"1":[35],"or":[36,71,177],"2,":[37],"were":[38,80,88,104,142,183],"eligible":[39],"for":[40,82,196,253],"this":[41],"multicenter":[42],"phase":[43],"II":[44],"trial.":[45],"All":[46],"received":[48],"four":[49],"weekly":[50],"doses":[51],"(375":[54],"mg/m(2)":[55],"intravenous),":[56],"followed":[57,90],"by":[58],"three":[59],"courses":[60],"combination":[62],"(either":[64],"cyclophosphamide,":[65,72],"doxorubicin,":[66],"vincristine,":[67,73],"prednisone":[69,75],"[CHOP],":[70],"[CVP])":[76],"plus":[77,187,235],"rituximab.":[78],"evaluated":[81],"response":[83,120,205],"after":[84],"completing":[85],"treatment,":[86],"then":[89],"up":[91],"at":[92,157,224],"3-month":[93],"intervals.":[94],"RESULTS:":[95],"Between":[96],"January":[97],"2000":[98],"July":[100],"2001,":[101],"86":[102],"treated.":[105],"Eight-two":[106],"(95%)":[108],"completed":[109],"treatment;":[110],"no":[111],"patient":[112],"was":[113,122,160],"withdrawn":[114],"due":[115],"to":[116,209,240],"toxicity.":[117],"The":[118,201,218],"overall":[119,154,202],"rate":[121],"93%,":[123],"55%":[125],"complete":[126,204],"responses.":[127],"After":[128],"a":[129],"median":[130],"follow-up":[131,231],"42":[133],"months,":[134],"3-":[136],"4-year":[138],"actuarial":[139,155,219],"progression-free":[140,220],"survivals":[141],"71%":[143],"62%,":[145],"respectively.":[146],"Five":[147],"(6%)":[149],"died":[150],"from":[151],"lymphoma;":[152],"survival":[156,221],"3":[158],"years":[159,226],"95%.":[161],"Grade":[162,179],"3/4":[163,180],"leukopenia":[164],"occurred":[165],"53%":[167],"patients,":[169],"but":[170,229],"only":[171],"six":[172],"(7%)":[174],"had":[175],"neutropenia":[176],"fever.":[178],"nonhematologic":[181],"toxicities":[182],"uncommon.":[184],"CONCLUSION:":[185],"Rituximab":[186,234],"short-course":[188,236],"is":[190,227,232],"well":[191],"tolerated":[192],"as":[193,242,244],"NHL.":[200],"rates":[206],"are":[207],"similar":[208],"those":[210],"reported":[211],"chemotherapy/rituximab":[213],"combinations":[214],"longer":[216],"duration.":[217],"62%":[223],"4":[225],"encouraging,":[228],"further":[230],"necessary.":[233],"may":[238],"prove":[239],"be":[241],"effective":[243],"longer-duration":[245],"currently":[248],"provides":[249],"an":[250],"attractive":[251],"option":[252],"elderly":[257],"others":[260],"who":[261],"tolerate":[262],"poorly.":[264]},"counts_by_year":[{"year":2017,"cited_by_count":1},{"year":2015,"cited_by_count":2},{"year":2014,"cited_by_count":2},{"year":2013,"cited_by_count":1},{"year":2012,"cited_by_count":3}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-06-24T00:00:00"}